Advanced Filters
noise

Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,299 clinical trials
P Paula Strussione

A Phase 1 Study of NM6603 in Advanced Solid Tumors

This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.

18 years of age All Phase 1
A Aron Popovzer, MD

A Study of Diffusing Alpha Radiation Therapy for Target Treatments of Malignant Tumors

This study is a Compassionate clinical study for the treatment of Malignant Tumors. The primary endpoint of the study is to assess the frequency, severity and causality of acute adverse events related to the DaRT treatment. Adverse events will be assessed and graded according to Common Terminology and Criteria for …

18 years of age All Phase N/A
X Xingchen Peng

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

To evaluate the safety of therapeutic immunological agent against EBV-positive advanced malignancies, examining the incidence, type of occurrence, and severity of adverse events in relation to the agent tested, and initially exploring the effectiveness of the immunological agent.

18 - 70 years of age All Phase 1
C Colin DEBAIGT

Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

This study aims to collect tumor samples from patients carrying a mutation of interest to develop a cell culture technique for "spheroids. The goal is to use these spheroids to model responses to anticancer treatments. Various therapeutic molecules can be tested on these spheroids, enabling the evaluation of the potential …

18 years of age All Phase N/A

Study of LM-299 in Subjects Advanced Malignant Tumors

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-299 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explorethe recommended dose for expansion (RDE) in patients with advanced solid tumours.. For Phase II Dose Expansion Stage, to …

18 - 80 years of age All Phase 1/2
W Wenqian Geng

A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors

This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.

18 - 75 years of age All Phase 1
W Weibing Miao, MD

Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation …

18 - 90 years of age All Phase N/A
H Huashan Shi, Doctor

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

The goal of this study is to evaluate the safety and efficacy of mRNA vaccine for the KRAS mutation malignant tumors.

18 years of age All Phase 1
C Colin DEBAIGT

Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA

This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.

18 years of age All Phase N/A

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors

18 years of age All Phase 1/2

Simplify language using AI